7 days or less is a rapid aHUS diagnosis
A rapid diagnosis of aHUS in 7 days or less usually results in the patient having the best of health outcomes…
A rapid diagnosis of aHUS in 7 days or less usually results in the patient having the best of health outcomes…
There are now licensed biosimilars to eculizumab available in Europe and also in the USA ( see previous article and further…
In making a choice aHUS patients’ preferences among treatments like eculizumab (and its biosimulars) , ravulizumab, crovalimab, and iptacopan it largely…
Our aHUS Alliance Global Action team takes to heart our mission to “Inform. Connect. Collaborate” on ideas and initiatives across all…
It is now just over 3 months since a discontinuing treatment decision making model was proposed to help aHUS patients make…
Intracellular complement, or “complosome,” refers to the complement system’s activity within cells, a discovery that has significantly expanded the understanding of…
On the 10th anniversary of international aHUS awareness day it is timely to raise awareness that the old term aHUS is…
The Global Action website has been featuring the pioneers and first events of aHUS history in its series Before aHUS Endeavours…
2024 – SEPT – 2025 Atypical HUS: Fact Sheets & Research Atypical Hemolytic Uremic Syndrome – a Rare Disease Information…